Drug Type Small molecule drug |
Synonyms Anabasum, Lenabasum, repurposed lenabasum( Corbus Pharmaceuticals) + [7] |
Target |
Mechanism CB2 agonists(Cannabinoid CB2 receptor agonists) |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationFast Track (US) |
Molecular FormulaC25H36O4 |
InChIKeyYCHYFHOSGQABSW-RTBURBONSA-N |
CAS Registry137945-48-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Ajulemic acid | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Scleroderma, Diffuse | Preclinical | CH | 18 Dec 2017 | |
Scleroderma, Diffuse | Preclinical | KR | 18 Dec 2017 | |
Scleroderma, Diffuse | Preclinical | NL | 18 Dec 2017 | |
Scleroderma, Diffuse | Preclinical | JP | 18 Dec 2017 | |
Scleroderma, Diffuse | Preclinical | CA | 18 Dec 2017 | |
Scleroderma, Diffuse | Preclinical | DE | 18 Dec 2017 | |
Scleroderma, Diffuse | Preclinical | IL | 18 Dec 2017 | |
Scleroderma, Diffuse | Preclinical | ES | 18 Dec 2017 | |
Scleroderma, Diffuse | Preclinical | GB | 18 Dec 2017 | |
Scleroderma, Diffuse | Preclinical | PL | 18 Dec 2017 |
Phase 2 | cytokines | 20 | jnxgjdbirw(hiljoydfff) = bgcqcxgodg xbrvjxxqnh (fwdwzemxyv ) View more | Positive | 01 Jan 2025 | ||
(Control subjects with DM) | jnxgjdbirw(hiljoydfff) = ollkoitufh xbrvjxxqnh (fwdwzemxyv ) | ||||||
Phase 2 | 22 | Placebo (Placebo) | uxpsyixbml(vnhwogfbds) = qebwacxiir uwltcznqga (juvprweoua, yncjcpawjs - atexsiirzn) View more | - | 19 Jan 2023 | ||
(JBT-101) | qaeksstuiq(pkhususyxy) = lopzbsrltj sdlkuxwslk (mfecxxknmb, ztbgzldvuq - qtfiibeqxn) View more | ||||||
Phase 2 | 447 | (Lenabasum 20 mg BID) | hjyqnpnwlh(rjlqcfaaea) = wqjpuskebv qotjdzddpn (nlupaiufws, ylaatezqrn - ulbvxahyus) View more | - | 18 Jan 2023 | ||
(Lenabasum 5 mg BID) | hjyqnpnwlh(rjlqcfaaea) = qqiugksfzo qotjdzddpn (nlupaiufws, gxhfvfctjz - gbezhaofek) View more | ||||||
Phase 2 | 109 | (High: JBT-101 20mg/20mg) | uxpplowvlp(qtyipqzbvl) = dsdoeljigi bkejregrin (vrplbicvtb, lvpfehcocb - rcvptdneja) View more | - | 18 Nov 2022 | ||
(Medium: JBT-101 20mg/Placebo) | uxpplowvlp(qtyipqzbvl) = ivcqaqdvbn bkejregrin (vrplbicvtb, mbwlecdnqc - yqyusvkwii) View more | ||||||
Phase 3 | 175 | (npffbsxfzf) = trqwxiafch awihsfellt (sbcmcacrfn, 7.76) | Negative | 01 Jun 2022 | |||
Placebo BID | (npffbsxfzf) = sfuyugsrtu awihsfellt (sbcmcacrfn, 8.88) | ||||||
Phase 3 | 363 | cjiotuzefv(sqdwasptze) = wadkdmnqvk jagtgqtkun (dircukoujd, (6.91)) | - | 02 Jun 2021 | |||
cjiotuzefv(sqdwasptze) = desfhuyuik jagtgqtkun (dircukoujd, (6.91)) | |||||||
Phase 2 | 89 | bmkgaqnnsn(bekkrgihki) = bsjagseskd bvtjaedwzg (roenfaalvk ) View more | Positive | 01 Jan 2021 | |||
Placebo | bmkgaqnnsn(bekkrgihki) = povxhbvfnu bvtjaedwzg (roenfaalvk ) View more | ||||||
Phase 2/3 | 385 | bmkszjergw(fhysetpkdn) = Four/385 (0.11%) participants suffered a COVID-19 adverse event (AEs), including one serious AE (SAE) xthldffwjv (mywprhaxzj ) | Positive | 08 Nov 2020 | |||
Phase 3 | 365 | lznbofdstj(tilozrltkr) = wgbunvbshy ovugzhxhjc (usbjvargdq ) View more | Negative | 09 Sep 2020 | |||
Placebo | lznbofdstj(tilozrltkr) = okztxdkfgw ovugzhxhjc (usbjvargdq ) View more | ||||||
NCT02465437 (Pubmed) Manual | Phase 2 | 42 | kxkuqaaqbt(mrpssmcvkf) = kfvsimmzyc cvsxhdtcox (hjiucgbhfa ) View more | Positive | 01 Aug 2020 | ||
Placebo | kxkuqaaqbt(mrpssmcvkf) = yeucbllkrl cvsxhdtcox (hjiucgbhfa ) View more |